Comparison of WHO Treatment of Acute Watery Diarrhea With or Without Probiotic (Bacillus Clausii) in Children
NCT ID: NCT06887374
Last Updated: 2025-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
184 participants
INTERVENTIONAL
2024-03-01
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Probiotic Use in Outcomes of Premature Birth
NCT05710575
Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children
NCT03539913
Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea
NCT00534170
Beneficial Bacteria to Prevent Malnutrition and Diarrhea in Pakistani Infants
NCT00118872
Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Lactose Solution
NCT03814668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic group
Patients received 2 billion spores of probiotic (Bacillus clausii) every 12 hours, contained in a small bottle along with standard treatment as per WHO guidelines.
Probiotic Bacillus Clausii
Patients were given 2 billion spores of probiotic (Bacillus clausii) every12 hours, contained in a small bottle.
No probiotic group
Patients received only standard treatment as per WHO guidelines.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic Bacillus Clausii
Patients were given 2 billion spores of probiotic (Bacillus clausii) every12 hours, contained in a small bottle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 6 to 59 months
* Suffering from acute watery diarrhea for ≤ 7 days
Exclusion Criteria
* With prior antibiotics use
* Children under study with duration of stay more than 5 days
* clinical signs of a coexisting acute systemic illness like pneumonia, sepsis, meningitis, severely malnourished
* Immunocompromised children
* Hypersensitivity to probiotics
* With prior probiotic administration
6 Months
59 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Muhammad Aamir Latif
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad Aamir Latif
Research Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Talha Hassan
Role: PRINCIPAL_INVESTIGATOR
Children Hospital, Lahore, Pakistan
Muhammad Zeeshan
Role: STUDY_DIRECTOR
Children Hospital, Lahore, Pakistan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children Hospital
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AWD-CH-LAHORE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.